Tatsuaki Morokata, Ph.D.

President, Astellas Innovation Management LLC
Drug Discovery Research
Astellas Pharma Inc.

 


Dr. Tatsuaki Morokata joined Astellas in 1995 (formerly Yamanouchi Pharmaceutical Co. Ltd.), and he currently manages Astellas Innovation Management LLC which are responsible for acquiring internal and external innovation opportunities in the preclinical development stage, including strategy planning, screening, scientific, assessment and alliance negotiations.

His other professional and managerial experience at Astellas include the following: Divisional Senior Vice President, Innovation & Incubation Research Labs and President, Astellas Innovation Management LLC (2018- March 2019); Executive Director, New Product Science Strategy Group, Product and Portfolio Strategy (2017-2018); Executive Director, ImmunoScience Research Unit, Research and Portfolio Science (2014-2016); Senior Director, Innovation Research Lab, Molecular Medicine Research Labs (2012-2013). Post Doctorial Research Fellow at Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School (2009 to 2010).

Dr. Morokata has more than 24 years of experience in immunology research from early to late stage drug discovery.
He received his Ph.D. in Pharmaceutical Science from the University of Tokyo.   

 

Mark (Makoto) Ohori, Ph.D. 

Executive Director, Head of Early-stage Partnering, AIM Cambridge

 

 


Dr. Mark (Makoto) Ohori is Executive Director, Head of Early-stage Partnering, Astellas Innovation Management Cambridge since April 2019. He most recently served as Senior Director, Head of AIM Cambridge DRY.

From 2016-2018, Mark was Visiting Scientific Director for Astellas Venture Management LLC (AVM, Menlo Park, CA) , working in-residence at Potenza Therapeutics (Cambridge, MA) where he served as Co-chair of the Joint Steering Committee overseeing a strategic immune-oncology research collaboration between the companies. 

Previously, Mark was an Investment Director at AVM from 2011, where he led investments in early-stage biotech companies (Potenza Therapeutics, Mitobridge, Verastem, eFFECTOR Therapeutics, Crescendo Biologics (UK), Bicycle Therapeutics, Cleave Biosciences, Tizona Therapeutics, PhaseBio, Viamet, etc) and established research partnerships with Potenza, Mitobridge and other portfolio companies or academic institutions, and facilitated acquisition of Potenza Therapeutics and Mitobridge by Astellas, or helped IPOs of Epizyme, Verastem, Fate Therapeutics, Taigen, etc.

Prior to AVM, Mark led biologics research in Astellas as a leader of the cross-organizational research team. He also worked at Post-Marketing Development Research Center at Fujisawa Pharmaceuticals to maximize the value of marketed products thorough clinical research collaborations with academia partners. He also managed research collaborations with academic institutions such as Dana-Farber Cancer Institute, Grenoble University Hospital, Dokkyo University School of Medicine, Kyoto University Hospital, or various CROs.
Mark has authored two patents and 16 peer reviewed papers and invited reviews. He received his Ph.D. in Pharmaceutical Sciences from the University of Tokyo.

 

Kazunori Inabe, Ph.D., M.B.A.

Executive Director, Head of Early-stage Partnering, AIM San Francisco

 

 


Dr. Inabe is the Head of Early-stage Partnering, AIM San Francisco since April 2019. He most recently served as Senior Director at Innovation Management, Drug Discovery Research, Astellas Pharma in Japan. There, he led a Japan-based team responsible for transaction and alliance management of projects in early-stage partnerships with biotech companies or academic institutions. In this role, he was involved in partnerships with nearly 20 biotech companies or academic institutions, such as Mitobridge, Inc., Proteostasis Therapeutics, and Harvard Medical School. He also served as a member of the Joint Steering Committee or Alliance Manager for the partnerships with Cytokinetics, Inc., Mitobridge, Inc. and Potenza Therapeutics, Inc.  

From 2009 to 2011, Dr. Inabe was a member of Astellas Venture Management LLC, a US-based corporate venture capital arm of Astellas Pharma, that is engaged in strategic investment activities in the biotech industry. Prior to joining Yamanouchi, the former company of Astellas, in 2002, Dr. Inabe’s career in life sciences included work as an Assistant Professor at Kansai Medical University, Osaka, Japan. He holds a Ph.D. in Medical Science from Hokkaido University and an M. B. A. from Globis University. 

 

Takeshi Kurama, Ph.D.

Director
AIM Cambridge

 

Naoto Nakamura, Ph.D.

Associate Director
AIM Cambridge

 

Tomohiro Yoshida

Associate Director
AIM Cambridge

 

 
Aya Hoshino, Ph.D.

Senior Manager
AIM Cambridge

 

Koichiro Tsuboi, Ph.D.

Senior Manager
AIM Cambridge

 

Akira Okajima

Senior Manager
AIM Cambridge

 

 
Mitsutoshi Wayama

Senior Manager
AIM Cambridge

 

 
Shingo Yamasaki, Ph.D.

Associate Director
AIM San Francisco

 

Takamitsu Ikeda, Ph.D.

Associate Director
AIM San Francisco

 

Munemichi Ohe, Ph.D.

Senior Manager
AIM San Francisco